H460 human lung cancer cells were used to determine whether the Rpa-RX3-AC complex-driven activation of the ARF-p53 pathway was sufficient to defend against oncogenic K-RAS-induced lung tumorigenesis. The gene discussed is TP53; the disease is lung cancer.